ABBV - AbbVie Inc.

NYSE - NYSE Delayed Price. Currency in USD
98.22
+0.77 (+0.79%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close97.45
Open97.84
Bid0.00 x 1400
Ask0.00 x 800
Day's Range97.06 - 98.65
52 Week Range69.47 - 125.86
Volume6,333,261
Avg. Volume8,248,698
Market Cap148.732B
Beta1.62
PE Ratio (TTM)24.38
EPS (TTM)4.03
Earnings DateOct 25, 2018 - Oct 29, 2018
Forward Dividend & Yield3.84 (4.10%)
Ex-Dividend Date2018-07-12
1y Target Est109.35
Trade prices are not sourced from all markets
  • NYSE trader: Expect stocks to churn this August
    Yahoo Finance Video8 days ago

    NYSE trader: Expect stocks to churn this August

    Keith Bliss of DriveWealth joins Yahoo Finance's Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves as stocks continue to churn. The materials and telecommunications sectors are leading, and the energy and consumer staples sectors are lagging.

  • Here’s What Tesaro’s Valuation Trend Indicates
    Market Realist13 hours ago

    Here’s What Tesaro’s Valuation Trend Indicates

    Tesaro’s (TSRO) Phase 3 PRIMA trial of Zejula to evaluate it for the treatment of women with newly diagnosed ovarian cancer, irrespective of BRCA mutation status, has been completely enrolled. Its Phase 2 trial of Zejula in combination with an anti-PD-1 antibody in first-line non-small cell lung cancer is ongoing. The company expects to present data in the first half of 2019. In its immuno-oncology pipeline, Tesaro plans to submit a BLA (Biologic License Application) for TSR-042 in 2019.

  • Analysts’ Expectations for Tesaro and Its Peers in August
    Market Realist13 hours ago

    Analysts’ Expectations for Tesaro and Its Peers in August

    Tesaro (TSRO) is a commercial-stage biopharmaceutical company primarily focused on developing treatments for solid tumors by using small molecules and immune-oncology antibodies both as monotherapies and in combinations. Tesaro’s key product, Zejula, has been approved in the United States as well as the European Union as a maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Tesaro commercialized Zejula in the United States in April 2017 and in Europe in December 2017.

  • Gauging Analysts’ Expectations for Novavax and Peers in August
    Market Realist14 hours ago

    Gauging Analysts’ Expectations for Novavax and Peers in August

    Novavax (NVAX) is a clinical-stage biotechnology company focused on bringing to market recombinant nanoparticle vaccines and adjuvants. Novavax makes use of its proprietary recombinant nanoparticle vaccine technology and saponin-based adjuvant technology to develop vaccine candidates that target different infectious diseases, such as the respiratory syncytial virus and influenza. Novavax has entered into a key grant agreement with the Bill and Melinda Gates Foundation (or BMGF), which is the current source of its revenue.

  • GlobeNewswire17 hours ago

    The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of COOL, TAL, FPI, ABBV and GDS

    NEW YORK, Aug. 16, 2018-- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead ...

  • A Look at the Performance of Bausch Health’s Ortho Dermatologics
    Market Realist17 hours ago

    A Look at the Performance of Bausch Health’s Ortho Dermatologics

    Bausch Health Companies’ (BHC) wholly-owned subsidiary Ortho Dermatologics generated revenue of $142.0 million in the second quarter compared to $162 million in the second quarter of 2017, reflecting a ~12% YoY (year-over-year) fall.

  • ACCESSWIREyesterday

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AbbVie Inc. - ABBV

    NEW YORK, NY / ACCESSWIRE / August 15, 2018 / is investigating claims on behalf of investors of AbbVie Inc. ("AbbVie" or the "Company") (ABBV). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980. The investigation concerns whether AbbVie and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

  • Barrons.comyesterday

    [$$] 5 Dividend Standouts

    Among the five companies with fast dividend growth cited in that earlier column, the highest yield was 1.4%, offered by UnitedHealth Group (UNH). All five of these companies have been able to grow their dividends rapidly, thanks to strong earnings growth over the past half-decade. One caveat: Only one of these firms—Regions Financial (RF)—has outperformed the S&P 500 this year in price appreciation.

  • See what the IHS Markit Score report has to say about AbbVie Inc.
    Markit3 days ago

    See what the IHS Markit Score report has to say about AbbVie Inc.

    AbbVie Inc NYSE:ABBV

  • Better Buy: AbbVie Inc. vs. Johnson & Johnson
    Motley Fool3 days ago

    Better Buy: AbbVie Inc. vs. Johnson & Johnson

    Which stock wins in a match-up between these two big pharma companies?

  • GlobeNewswire3 days ago

    SHAREHOLDER ALERT: HAIR RMTI ABBV GDS NLSN ZN SBGI ORCL: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

    NEW YORK, Aug. 13, 2018-- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead ...

  • PR Newswire4 days ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AbbVie Inc. - ABBV

    NEW YORK , Aug. 13, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AbbVie Inc. ("AbbVie" or the "Company") (NYSE: ABBV).   Such investors are advised ...

  • Top Analyst Reports: Mastercard, AbbVie, Twenty-First Century Fox & More
    Zacks4 days ago

    Top Analyst Reports: Mastercard, AbbVie, Twenty-First Century Fox & More

    Top Analyst Reports: Mastercard, AbbVie, Twenty-First Century Fox & More

  • InvestorPlace4 days ago

    Why Enanta Stock Is Still a Strong Buy With Huge Upside

    Enanta Pharmaceuticals (NASDAQ:ENTA) has been in the news recently. Before I get around to what’s been happening with ENTA stock recently, it may help to get a broader understanding of how the company operates and what exactly it does. What used to be a fairly typical model, where you discover a drug, run it through the various drug trials, build a marketing plan and sell the drug, has now become much more focused.

  • GlobeNewswire5 days ago

    SHAREHOLDER ALERT: MRCY GLNCY GLCNF MD FPI FIZZ SBGL ACAD ABBV TTPH RMTI: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

    NEW YORK, Aug. 12, 2018-- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead ...

  • InvestorPlace7 days ago

    You Better Be Careful with Merck Stock, Especially at These Highs

    Health care stocks including pharmaceutical giant Merck (NYSE:MRK) have gone on a nice run of late. Merk stock has gained over 20% just since early April, touching an all-time high this week. Q1 earnings that month seemed mixed, but the market reacted positively, and Merck raised guidance in the Q2 report late last month.

  • Benzinga7 days ago

    Jim Cramer Weighs In On Arch Coal, AbbVie And More

    Jim Cramer said on CNBC's "Mad Money Lightning Round" that he spoke to Magna International Inc. (USA) (NYSE: MGA ) and it didn't leave him warm and fuzzy about the group. He wants to be careful ...

  • CNBC7 days ago

    Cramer Remix: Trade sanctions are hurting hedge funds the most

    CNBC's Jim Cramer breaks down why hedge funds are feeling the pain when it comes to tariffs. The "Mad Money" host also sits down with the CEOs of Magna International and Cyberark Software. In the lightning round, Cramer backs the stock of AbbVie despite the bear thesis.

  • CNBC7 days ago

    Cramer's lightning round: Coal may be in a renaissance, but don't buy the stocks

    It's that time again! "Mad Money" host Jim Cramer rang the lightning round bell, which means he gave his take on callers' favorite stocks at rapid speed. Arch Coal, Inc. ARCH : "Coal is enjoying a bit of a renaissance, I have to admit. Transenterix, Inc. TRXC : "I like Intuitive Surgical ISRG .

  • 53 Best Dividend Stocks for 2018 and Beyond
    Kiplinger7 days ago

    53 Best Dividend Stocks for 2018 and Beyond

    Dividend stocks that can be counted on to raise their payouts annually never go out of style, but they're even more compelling given today's investing landscape. Investment strategists at S&P Dow Jones Indices note that stocks with long histories of dividend growth can be an investor's best friend amid market volatility and rising interest rates. "Dividend growth stocks tend to be of higher quality than those of the broader market in terms of earnings quality," write S&P strategists Tianyin Cheng and Vinit Srivastava. "Quite simply, when a company is reliably able to boost its dividend for years or even decades, this may suggest it has a certain amount of financial strength and discipline." And don't forget: steady dividend hikes not only make a stock more alluring to new income investors, but also reward existing investors with increasingly higher yields on shares purchased at lower prices in the past. The Dividend Aristocrats are companies in the Standard & Poor's 500-stock index that have hiked their payouts every year for at least 25 consecutive years. They exemplify a winning formula for investing in dividend growth stocks. Here are the current Dividend Aristocrats - a list of household names that offer size, longevity and familiarity, providing comfort amid market uncertainty. These are 53 of the best dividend stocks to start looking at for investors seeking out high-quality companies to add to their long-term portfolios. SEE ALSO: The 50 Best Stocks of All Time

  • GlobeNewswire8 days ago

    CLASS ACTION UPDATE for FPI and ABBV: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

    NEW YORK, Aug. 09, 2018-- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving ...

  • ACCESSWIRE8 days ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AbbVie Inc. - ABBV

    NEW YORK, NY / ACCESSWIRE /August 8, 2018 / is investigating claims on behalf of investors of AbbVie Inc. ("AbbVie" or the "Company") (ABBV). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980. The investigation concerns whether AbbVie and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

  • Investor's Business Daily8 days ago

    Mylan Exploring Options As 'Unsustainable' Trends Hound Sales, Profit

    Mylan stock tumbled after the drugmaker missed second-quarter expectations, issued lagging guidance for 2018 and announced a strategic review.

  • Mylan (MYL) Q2 Earnings and Revenues Miss, Guidance Cut
    Zacks9 days ago

    Mylan (MYL) Q2 Earnings and Revenues Miss, Guidance Cut

    Mylan is expected to loose ground after its second-quarter results miss estimates. The cut in guidance is disappointing as well.

  • These Products Contributed to Pfizer’s Growth in Q2 2018
    Market Realist9 days ago

    These Products Contributed to Pfizer’s Growth in Q2 2018

    Pfizer’s (PFE) product portfolio includes both Innovative Health products and Essential Health products.